AbbVie (NYSE:ABBV) has broken ground on a $70M expansion of an existing site in Worcester, Mass., that serves as a biologics R&D center and manufacturing facility.
The company said the additional space will boost its biologics manufacturing capacity. The plan also calls for a three-story building for laboratory, warehouse, and office space. Also, the new facilities will speed up the transfer of some oncology therapies from Europe to the U.S.
During its Q1 earnings call in late April, AbbVie management said it would invest $10B to improve its supply chain in the US.
